Efficacy and safety of valbenazine in Japanese patients with tardive dyskinesia: A multicenter, randomized, double‐blind, placebo‐controlled study (J‐KINECT)

AIM: Valbenazine is approved in the US for treatment of tardive dyskinesia (TD); however, efficacy/safety data in Asian populations are lacking. We assessed the efficacy/safety of valbenazine in Japanese patients. METHODS: This phase II/III, multicenter, randomized, double‐blind, placebo‐controlled...

Descripción completa

Detalles Bibliográficos
Autores principales: Horiguchi, Jun, Watanabe, Koichiro, Kondo, Kazuoki, Iwatake, Atsushi, Sakamoto, Hajime, Susuta, Yutaka, Masui, Hideaki, Watanabe, Yumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2022
Materias:
Regular Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9826124/
https://www.ncbi.nlm.nih.gov/pubmed/36114799
http://dx.doi.org/10.1111/pcn.13455

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9826124/
https://www.ncbi.nlm.nih.gov/pubmed/36114799
http://dx.doi.org/10.1111/pcn.13455

Ejemplares similares